ACADIA Pharmaceuticals (ACAD) Getting Somewhat Favorable Media Coverage, Analysis Shows

News coverage about ACADIA Pharmaceuticals (NASDAQ:ACAD) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.0341317405821 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

ACADIA Pharmaceuticals (ACAD) traded down $1.07 on Friday, reaching $30.11. 846,800 shares of the company’s stock traded hands, compared to its average volume of 1,330,000. The stock has a market capitalization of $3,820.00, a P/E ratio of -12.24 and a beta of 3.80. ACADIA Pharmaceuticals has a fifty-two week low of $25.06 and a fifty-two week high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.10. The business had revenue of $35.58 million for the quarter, compared to the consensus estimate of $32.03 million. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The company’s revenue was up 571.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.61) earnings per share. analysts forecast that ACADIA Pharmaceuticals will post -2.41 earnings per share for the current year.

A number of analysts recently issued reports on ACAD shares. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $50.00 price target (up from $48.00) on shares of ACADIA Pharmaceuticals in a report on Monday, October 2nd. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 price target on shares of ACADIA Pharmaceuticals in a report on Friday, October 6th. Leerink Swann reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Monday, October 9th. Needham & Company LLC reissued a “buy” rating and set a $49.00 price target on shares of ACADIA Pharmaceuticals in a report on Sunday, September 17th. Finally, Bank of America increased their price target on shares of ACADIA Pharmaceuticals from $40.00 to $46.00 and gave the stock a “positive” rating in a report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $48.86.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 37,500 shares of the stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $40.91, for a total transaction of $1,534,125.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 22.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/12/31/acadia-pharmaceuticals-acad-getting-somewhat-favorable-media-coverage-analysis-shows.html.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit